Corvus expects full year 2024 net cash used in operating activities to be between approximately $24M and $27M, resulting in a projected cash balance of between approximately $31M and $34 M at December 31. Based on its current plans, Corvus expects its cash to fund operations into the fourth quarter of 2025. Research and development expenses for the three months ended June 30 totaled $4.1M compared to $4M for the same period in 2023. The increase of $0.1M was primarily due to higher clinical trial costs associated with the development of soquelitinib.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVS:
- Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results
- CRVS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Biotech Alert: Searches spiking for these stocks today
- Corvus Pharmaceuticals granted FDA Fast Track Designation for soquelitinib
- Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024